Stanford School of Medicine
Multidisciplinary Cutaneous Lymphoma Group–

Publications

The publication page is designed to update our visitors on selected publications from our cutaneous lymphoma group. This information can serve as a general reference guide on cutaneous lymphomas and to learn about our selected research activities.

These papers are available through online reference libraries or Stanford’s Lane Medical Library resources.


  1. Smoller BR, Bishop K, Glusac EJ, Kim YH, et al: Reassessment of lymphocyte immunophenotyping in the diagnosis of patch and plaque stage lesions of mycosis fungoides. Applied Immunohistochem 3:32-36, 1995.
  2. Smoller BR, Bishop K, Glusac E, Kim YH, Hendrickson M: Reassessment of histologic parameters in the diagnosis of mycosis fungoides. Am J Surg Pathol 19:1423-1430, 1995.
  3. Wood GS, Hardman DL, Boni R, Dummer R, Kim YH, et al: Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin’s disease. Blood 88:1765-70, 1996.
  4. Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT: Clinical stage IA (limited patch/plaque) mycosis fungoides: a long-term outcome analysis. Arch Dermatol 132:1309-1313, 1996.
  5. Wood GS, Salvekar A, Schaffer J, Crooks CF, Henghold W, Fivenson D, Kim YH, Smoller BR:  Evidence against a role for HTLV-I in the pathogenesis of American cutaneous T-cell Lymphoma.  J Invest Dermatol 107:301-7, 1996
  6. Kohler S, Kim YH, Smoller BR: Histologic criteria for the diagnosis of erythrodermic mycosis fungoides and Sezary syndrome: a critical reappraisal. J Cutan Pathol 24:292-297, 1997.
  7. Smoller BR. Detwiler SP, Kohler S, Hoppe RT, Kim YH: Role of histology in providing prognostic information in mycosis fungoides. J Cutaneous Pathol 25:311-5, 1998.
  8. Crowley JJ, Nikko A, Hoppe RT, Kim YH:  Mycosis fungoides in young patients: characteristics and outcome.  J Am Acad Dermatol 38:696-701, 1998
  9. Kim YH, Chow S, Varghese A, Hoppe RT: Clinical Characteristics and Long-Term Outcome of Patients with Generalized Patch and/or Plaque (T2) Mycosis Fungoides. Arch Dermatol 135:26-32, 1999.
  10. Chinn DM, Chow S, Kim YH, Hoppe RT: Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 Mycosis Fungoides. Int J Radiat Oncol Biol Phys 43:951-958, 1999.
  11. Chui CT, Hoppe RT, Kohler S, Kim YH: Epidermotropic cutaneous B-cell lymphoma mimicking mycosis fungoides. J Am Acad Dermatol, 41:271-274, 1999.
  12. Kim YH, Hoppe RT:  Mycosis fungoides and the Sézary syndrome.   Semin Oncol 26:276-289, 1999
  13. Olsen E, Duvic M, Frankel A, Kim YH, Martin A, et al:  Pivotal phase III trial of two dose levels of DAB389IL-2(ONTAK) for the treatment of cutaneous T-cell lymphoma.  J Clin Oncol, 19:376-388, 2000
  14. Natkunam Y, Warnke RA, Haghighi B, Kim YH, et al: Co-Expression of CD56 and CD30 in primary cutaneous lymphomas: clinicopathologic, immunohistochemical and molecular analyses of seven cases. J Clin Pathol 27:392-399, 2000.
  15. De Coninck E, Kim YH, Hoppe RT:  Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides.    J Clin Oncol, 19:779-784, 2001
  16. Mraz-Gernhard S, Hoppe RT, Natkunam Y, LeBoit P, Kohler S, Kim YH:  Natural killer/natural killer-like T-cell lymphoma (CD56+) presenting in the skin: an increasingly recognized entity with an aggressive course.   J Clin Oncol 19:2179-2188, 2001
  17. Duvic M, Martin AG, Kim YH, Olsen E, Wood G, et al:  Phase 2-3 clinical trial of oral Targrein (Bexarotene) capsules for the treatment of refractory or persistent early stage cutaneous T-cell lymphoma.  Arch Dermatol 137:581-593, 2001
  18. Liu HL, Kim YH:  Bexarotene gel: a food and drug administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma.    Arch Dermatol 138:398-9, 2002
  19. Kim YH, Martinez G, Varghese A, Hoppe RT:  Management with topical nitrogen mustard in mycosis fungoides: update of the Stanford Experience.   Arch Dermatol 139:165-173, 2003
  20. Storz MN, van de Rijn M, Kim YH, Mraz-Gernhard S, Hoppe RT, Kohler S:  Gene expression profiles of cutaneous B-cell lymphoma.    J Invest Dermatol 120:865-870, 2003
  21. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT:  Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression.    Arch Dermatol 139:857-866, 2003
  22. Liu HL, Kohler S, Harvell J, Hoppe RT, Kim YH:  Primary cutaneous CD30+ lymphoproliferative disorder: the Stanford experience of 56 patients.   J Am Acad Dermatol 49:1049-1058, 2003
  23. Kim YH: Management with topical nitrogen mustard in mycosis fungoides. In “Diagnosis and Treatment of Cutaneous T-cell Lymphoma” issue of Dermatologic Therapy, Blackwell Science, Inc. Wood GS, guest editor, Tharp MD, editor-in-chief. Volume 16, pp 288-298, 2003.
  24. Demierre M-F, Kim YH, Zackheim HS: Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma. In “Cutaneous Lymphoma” issue of Hematology/Oncology Clinics of North America, Elsevier Science/W.B. Saunders. Demierre M-F, Foss FM, guest editors, Holland KK, editor-in-chief. Volume 17, pp 1485-1507, 2003.
  25. Horwitz SM, Duncan L, Kim YH, Hoppe RT:  Cutaneous B-cell Lymphomas. In Non-Hodgkin's Lymphomas.   JO Armitage, P Mauch, R Dalla Favera, NL Harris, editors, Lippincott Williams & Wilkins, Philadelphia, pp. 319-331, 2004
  26. Kadin ME, Liu HL, Kim YH, Hoppe RT:  CD30+ Cutaneous Lymphoprolifertave Disease: Anaplastic Large Cell Lymphoma and Lymphomatoid Papulosis. In Non-Hodgkin's Lymphomas.   JO Armitage, P Mauch, R Dalla Favera, NL Harris, editors, Lippincott Williams & Wilkins, Philadelphia, pp. 333-343, 2004
  27. Hoppe RT, Harvell JD, Kim YH:  Mycosis Fungoides. In Non-Hodgkin's Lymphomas.   JO Armitage, P Mauch, R Dalla Favera, NL Harris, editors, Lippincott Williams & Wilkins, Philadelphia, pp. 307-318, 2004
  28. Beynet DP, Wee SA, Horwitz S, Kohler S, Horning S, Hoppe R, Kim YH: Clinical and pathologic features of posttransplant lymphoproliferative disorders presenting with skin involvement in 4 patients. Arch Dermatol 140:1140-1146, 2004.
  29. Sundrum U, Kim YH, Mraz-Gernhard S, Hoppe RT, Natkunam Y, Kohler S: Expression of the bcl-6 and MUM1/IRF4 Proteins Correlate with Overall and Disease-Specific Survival in Patients with Primary Cutaneous Large B-cell Lymphoma: A Tissue Microarray Study. J Cutan Pathol 32:227-34,2005.
  30. Hoppe RT, Kim YH, Advani R: Mycosis Fungoides and the Sezary Syndrome. In Cancer Medicine, 7th Edition. Holland and Frei, editors, Hamilton, B.C. Decker, Inc., 2005.
  31. Tsai EY, Hoppe RT, Espinosa L, Taur A, Kohler S, Dick S, Chow S, Warnke R, McDougall R, Kim YH: Staging accuracy in mycosis fungoides/Sézary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol 142:577-84, 2006.
  32. Kim YH, Advani R, Hoppe RT: Mycosis Fungoides and Sezary Syndrome. In The Lymphoid Neoplasms, 3rd Edition. I Magrath and A Rohatiner, editors, Arnold and Oxford University Press, In Press, 2006.
  33. Jayaraman AG, Cassarino D, Advani R, Tsai EY, Kim YH, and Kohler S: Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology. J Cutan Pathol, 2006.
  34. Hoppe RT, Kim YH: Mycosis Fungoides and the Sézary Syndrome. In UpToDate online clinical reference. Burton D. Rose, Editor-in-Chief, Wellesley, Massachusetts

Footer Links: